Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Gains from Investment Securities: 2014-2024

Historic Gains from Investment Securities for Iovance Biotherapeutics (IOVA) over the last 9 years, with Dec 2024 value amounting to $12.9 million.

  • Iovance Biotherapeutics' Gains from Investment Securities fell 92.58% to $466,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $7.5 million, marking a year-over-year decrease of 38.39%. This contributed to the annual value of $12.9 million for FY2024, which is 360.04% up from last year.
  • As of FY2024, Iovance Biotherapeutics' Gains from Investment Securities stood at $12.9 million, which was up 360.04% from $2.8 million recorded in FY2023.
  • In the past 5 years, Iovance Biotherapeutics' Gains from Investment Securities ranged from a high of $21.4 million in FY2020 and a low of $2.6 million during FY2022.
  • Moreover, its 3-year median value for Gains from Investment Securities was $2.8 million (2023), whereas its average is $6.1 million.
  • As far as peak fluctuations go, Iovance Biotherapeutics' Gains from Investment Securities crashed by 87.56% in 2022, and later skyrocketed by 360.04% in 2024.
  • Iovance Biotherapeutics' Gains from Investment Securities (Yearly) stood at $21.4 million in 2020, then dropped by 0.47% to $21.3 million in 2021, then crashed by 87.56% to $2.6 million in 2022, then increased by 5.51% to $2.8 million in 2023, then surged by 360.04% to $12.9 million in 2024.